A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease - Wikidata - wikimedia - TriplyDB

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

http://www.wikidata.org/entity/Q34493731

about

Putative Role of Red Wine Polyphenols against Brain Pathology in Alzheimer's and Parkinson's Disease Challenges in Analyzing the Biological Effects of Resveratrol Recent Advances in Neurogenic Small Molecules as Innovative Treatments for Neurodegenerative Diseases Curcumin and Resveratrol in the Management of Cognitive Disorders: What is the Clinical Evidence?Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges The evidence for natural therapeutics as potential anti-scarring agents in burn-related scarring Slowing ageing by design: the rise of NAD(+) and sirtuin-activating compounds Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential A genomics approach identifies selective effects of trans-resveratrol in cerebral cortex neuron and glia gene expression.Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations.Therapeutic Effects of Phytochemicals and Medicinal Herbs on Depression.The Repeated Administration of Resveratrol Has Measurable Effects on Circulating T-Cell Subsets in Humans.Nutritional and Pharmacological Strategies to Regulate Microglial Polarization in Cognitive Aging and Alzheimer's Disease.Effects of resveratrol on drug- and carcinogen-metabolizing enzymes, implications for cancer prevention.Resveratrol supplementation confers neuroprotection in cortical brain tissue of nonhuman primates fed a high-fat/sucrose diet.Resveratrol attenuates acute kidney injury by inhibiting death receptor‑mediated apoptotic pathways in a cisplatin‑induced rat model.Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease.Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans.Impact of Resveratrol on Glucose Control, Hippocampal Structure and Connectivity, and Memory Performance in Patients with Mild Cognitive Impairment.The Immunomodulatory Effects of Plant Extracts and Plant Secondary Metabolites on Chronic Neuroinflammation and Cognitive Aging: A Mechanistic and Empirical Review.Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.Resveratrol as a Natural Autophagy Regulator for Prevention and Treatment of Alzheimer's Disease.The NAD+-Dependent Family of Sirtuins in Cerebral Ischemia and Preconditioning.The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.Oleuropein aglycone and polyphenols from olive mill waste water ameliorate cognitive deficits and neuropathology.Caloric restriction: beneficial effects on brain aging and Alzheimer's disease.Alzheimer's Disease: From Mitochondrial Perturbations to Mitochondrial Medicine.The role of modulation of antioxidant enzyme systems in the treatment of neurodegenerative diseases.Sirtuins as modifiers of Parkinson's disease pathology.Association between high consumption of phytochemical-rich foods and anthropometric measures: a systematic review.Olive polyphenols: new promising agents to combat aging-associated neurodegeneration.Targeting extracellular matrix remodeling in disease: Could resveratrol be a potential candidate?Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.Health-beneficial nutraceuticals-myth or reality?Vascular inter-regulation of inflammation: molecular and cellular targets for CNS therapy.Could Sirtuin Activities Modify ALS Onset and Progression?Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications.Modulation of innate immunity of patients with Alzheimer's disease by omega-3 fatty acids.Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics.Gene Therapy in the Nervous System: Failures and Successes.

P2860

Q26738450-E27497E5-DAE7-4409-9213-8CA24B370FB0 Q26746257-11A51C31-F0AF-4888-B348-BA87786B2CA1 Q28069509-D4CF0B3D-CE0F-48AA-8616-66181B926D1F Q28071699-CB371481-7B06-4877-A16C-456A4FF3F8C6 Q28072061-7CCFCC78-73BA-40B7-96BF-FB4A34717396 Q28077410-1193576F-D45B-4B97-AF3E-7E46C2DDE746 Q28314993-D0C4CD35-2C1A-48F2-86B5-72BE6D318BCA Q29994589-6FCFB02B-9D49-45E9-88F6-888EFD2BFE73 Q33602768-4AD8B73C-46EE-4395-8D24-C0F54120AF57 Q33624653-A567347A-073E-4810-9B6A-2C43F2E40D5C Q33630966-0F6CBE1D-8E16-4A23-8D0B-11DEF46C02A5 Q33701615-6DD5C893-191B-4A7D-9900-D2435225F089 Q33770234-22E3004D-CA85-49D4-8C6B-FF20EAD7EEE2 Q33771427-0B23B6C4-8084-4300-888C-D8F8D2D414CC Q37062478-51810477-5CE1-4E85-8E1B-5047B7AF0DC0 Q37297507-B1970101-A4D7-4904-B194-F6E07BFAE875 Q37584887-47500B0F-6602-4AC4-B95F-9F3D909B1EE0 Q37653312-5741BF51-7924-48E3-97BC-BF3C1A450B0A Q37683181-EF5C5EDE-B1A9-4C32-A148-162CA3DECBE5 Q37692206-65724263-363A-4FBB-B791-862252F92D21 Q37730520-AF00BA2C-14C0-4A52-9DCF-5D391BA0240B Q38637798-88E0762B-9F5E-40E2-B88A-7EAC6DD04609 Q38661899-381DFB9A-3501-4A8F-9643-18054753F627 Q38672062-09810DDE-A936-4C02-A6CD-1073617C2587 Q38821665-705028F5-B226-40EB-9C17-9DAA25A615EE Q38848268-3BDE4650-D0EB-461F-AB3A-6FFAAA5DA05A Q38872085-CDB63E86-41C2-424F-9F11-B49620D7528B Q38889475-07D413E3-0442-40DC-9234-6499519C2E98 Q38893382-BEF86F73-B884-4A8D-B5B4-3D0DBA949E22 Q38949627-5BAAA7EC-9BBD-4BFE-83CF-6E72F4F482C6 Q38985937-48D6FD0F-83D2-4121-A292-5822850107D1 Q38995157-12092CBD-D4A7-4167-890F-CC67E92FDE2E Q39022532-2B87B908-8D87-45C1-888B-AB964F99D8AB Q39030138-39434DDF-736E-45AD-94E4-9F534FA8CB4A Q39031301-B3946493-0ECC-44A5-B6A7-4003A53E9835 Q39036105-60F088BA-3CF7-4662-A72E-13A13BE7ED3A Q39170234-DF6E24DE-1677-4DBE-A48C-C0B570641D04 Q39249384-B63B7EDF-6B9B-4B3D-8CBB-DD37F72E2AC8 Q39689655-EFDEA78D-3A1F-43DF-8A88-C7F5FDE3D647 Q40070708-A044FA31-FC38-4346-86FC-A389B0F9A105

P2860

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

http://www.wikidata.org/entity/Q34493731

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

@ast

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

@en

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

@nl

type

label

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

@ast

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

@en

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

@nl

prefLabel

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

@ast

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

@en

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

@nl

P1433

Q34493731-B6155469-2376-42E1-8715-CD57DD9A573C

P1476

Q34493731-F9710A96-509D-4592-88AF-7700C74D6CB3

P2093

Q34493731-2DCBD73E-2E2B-4573-AE05-B39B5D45121E

Q34493731-63250E50-4F8A-46CC-AC81-AFFA4AAD595E

Q34493731-7CC26A40-5219-4DB5-92AE-0E66C160CFAE

Q34493731-8D8DC446-56D7-42B4-9C14-7AA5B623CF96

Q34493731-921CF0C5-E054-408D-92A1-75A7E7A55AE3

Q34493731-B13B2F97-E3C5-41BE-9B9B-257EE70A6ED7

Q34493731-B1FBA889-80F1-4E67-AA4C-EAF8648975AA

Q34493731-C2C1B4E2-D522-486F-A078-BEAC1EAF331F

Q34493731-D8B7E500-4420-4784-A403-E0AD3061CC89

P2860

Q34493731-0418E26E-A9D7-458D-9D47-B83BF4D9AEDF

Q34493731-07B70B4A-3C33-4129-9686-ED6BA935E123

Q34493731-11434AE9-7BA5-4B57-92B4-6666DCEC028D

Q34493731-1279DB3E-002A-42A7-9D4A-968AAC5A0F17

Q34493731-13783F52-3D63-4D2D-9136-2E65A6762713

Q34493731-17BF7F51-2457-45DC-B8C0-1E2D3DC6CD43

Q34493731-1D2F651A-5601-48AD-9F7F-5BC00F18D262

Q34493731-1F5AF84A-7522-4C71-866E-F8D36F4281F9

Q34493731-21F1DA31-E18A-499F-A5A2-8DA8B78E4A2E

Q34493731-23FBAFC1-8689-428A-8FE9-88D2F888E2B3

P304

Q34493731-FDF7DF86-481C-420B-93E6-37825B4319ED

P31

Q34493731-65681A85-2AFC-4E37-A1EE-418D0BD77209

P356

Q34493731-3287325E-EF81-43C2-9409-B6CA5915207F

P407

Q34493731-DC20C6C1-8792-420E-A545-1BDCCF11D8E7

P433

Q34493731-887CD4EF-C837-47A8-843C-9ABC2498E910

P478

Q34493731-A9AA21BD-D8DF-40C7-96D2-9672D0B42E3E

P50

Q34493731-D6D8C1FD-E28A-4BA0-88D9-B7219C895B3D

Q34493731-EDE5FE9C-1938-4D3E-8FF2-BD3C5916BA1C

P577

Q34493731-4B8FB090-DE73-4F42-9EA9-0233DE7E2F9A

P698

Q34493731-FE268340-9080-44C7-8138-3926AB926842

P921

Q34493731-116D8751-71C2-4A74-A0B4-CDC365A6EF72

Q34493731-96D336CB-9B9F-41F9-BDAF-764139957E13

P932

Q34493731-FCC0B795-2690-4E32-B74E-FB94E49FE046

P356

WNL.0000000000002035

P1433

P1476

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

@en

P2093

Alzheimer's Disease Cooperative Study

http://www.w3.org/2001/XMLSchema#string

Brigid A Reynolds

http://www.w3.org/2001/XMLSchema#string

Christopher H van Dyck

http://www.w3.org/2001/XMLSchema#string

Jacobo Mintzer

http://www.w3.org/2001/XMLSchema#string

James B Brewer

http://www.w3.org/2001/XMLSchema#string

Rema Raman

http://www.w3.org/2001/XMLSchema#string

Robert A Rissman

http://www.w3.org/2001/XMLSchema#string

Ronald G Thomas

http://www.w3.org/2001/XMLSchema#string

Suzanne Craft

http://www.w3.org/2001/XMLSchema#string

P2860

Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase

SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10.

Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence

“Mini-mental state”

The molecular targets of resveratrol

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan

Energy intake and exercise as determinants of brain health and vulnerability to injury and disease

Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain

The Clinical Dementia Rating (CDR): current version and scoring rules

P304

1383-1391

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0000000000002035

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26362286

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4626244

http://www.w3.org/2001/XMLSchema#string